1-2 of 2
Anna Piotrowski
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase Ib/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab and Lenalidomide in Refractory/Recurrent Primary (PCNSL) and Secondary Central Nervous System Lymphoma (SCNSL)

Christian Grommes, Anna Piotrowski, Elena Pentsova, Igor Gavrilovic, Jacqueline B Stone, Andrew Lin, Venissala Wongchai, Juli T Madzsar, Rachna Malani, Craig Nolan, Jasmine Francis, Lisa DeAngelis, Lauren Schaff, Ingo K Mellinghoff
Journal: Blood
Blood (2022) 140 (Supplement 1): 3807–3808.
https://doi.org/10.1182/blood-2022-157001
Published: 2022
Journal Articles

Phase Ib Trial with Dose Expansion of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab and Lenalidomide in Patients with Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Christian Grommes, MD, Anna Piotrowski, MD, Elena Pentsova, MD, Craig Nolan, MD, Jasmine Francis, Lisa DeAngelis, MD, Lauren Schaff, MD, Ingo K Mellinghoff, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 48.
https://doi.org/10.1182/blood-2020-143075
Published: 2020